Renovascular hypertension
Also known as: Hypertension, High blood pressure, Elevated, Secondary
Methodology & AI Transparency ⓘ
Renovascular hypertension Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Renovascular hypertension uses ICD-10 I15.0 across Blood Pressure specialty care.
- 3 Typical cash cost range: Clinicians assessing Renovascular hypertension focus on elevated systemic vascular in Renovascular hypertension (I15.0: resistance) and targeted history.
- 4 Top reported side effects / signs: Key Blood Pressure biomarkers for Renovascular hypertension (I15.0): Urine Albumin-to-Creatinine Ratio [Renovascular hypertension I15.0] & Home Seated Blood in Renovascular hypertension (I15.0: Pressure) (< 120/75 mmHg (I15.0)).
Ask our AI Specialists anything about Renovascular hypertension
What Is Renovascular hypertension?
Recognized across U.S. clinical coding as I15.0 (Blood Pressure), Renovascular hypertension (also termed Hypertension or High blood pressure) is evaluated via duplex vascular ultrasonography [Renovascular hypertension I15.0] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Renovascular hypertension (I15.0) alters blood pressure homeostasis through elevated systemic vascular in Renovascular hypertension (I15.0: resistance); clinical remission targets Home Seated Blood in Renovascular hypertension (I15.0: Pressure) within < 120/75 mmHg (I15.0).
Common Symptoms & Clinical Signs
- • Presentation of Renovascular hypertension (I15.0): calf cramping or in Renovascular hypertension (I15.0: claudication triggered by)
- • Secondary Renovascular hypertension clinical sign: localized extremity swelling, in Renovascular hypertension (I15.0: warmth, or venous)
- • Symptom flares in Renovascular hypertension correlating with Urine Albumin-to-Creatinine Ratio [Renovascular hypertension I15.0] deviation outside < 15 mg/g (I15.0)
- • Functional blood pressure impact requiring duplex vascular ultrasonography [Renovascular hypertension I15.0] evaluation (I15.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Renovascular hypertension Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I15.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio [Renovascular hypertension I15.0] | < 15 mg/g (I15.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Home Seated Blood in Renovascular hypertension (I15.0: Pressure) | < 120/75 mmHg (I15.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Renovascular hypertension I15.0] | 1.00 – 1.30 (I15.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Renovascular hypertension
Treatment selection for Renovascular hypertension depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Renovascular hypertension)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Fixed dose combination of aspirin and pantoprazole: Results of a multicenter,: What a 240-Participant Study Found The fixed-dose combination of aspirin 150 mg and pantoprazole 20 mg was found to be more efficacious and safer compared to aspirin 150 mg alone for the prevention of gastroduodenal mucosal damage in patients receiving aspirin. Indian heart journal • 2024-01-15 • Phase III Randomized Trial | N = 240 | 88/100 | PMID 39009075 ↗ |
| New Insights on Long-term efficacy and tolerability of telmisartan as single-drug treatment and: What a 690-Participant Study Found All treatments were well tolerated. Blood pressure • 2002-01-15 • Randomized Controlled Trial | N = 690 | 87/100 | PMID 12458653 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Morning versus Bedtime Telmisartan on Ambulatory Blood Pressure and Bedtime telmisartan dosage improves nocturnal BP control, but morning dosage more successfully lowers exercise-induced BP spikes. The Nigerian postgraduate medical journal • 2026-03-01 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 41766266 ↗ |
| Can This Approach Help? Inside the Latest Research on Calcium channel blocker and Rho-associated kinase activity in patients with high These findings suggest that calcium channel blocker amlodipine inhibits ROCK activity in patients with high blood pressure. Journal of hypertension • 2011-02-15 • Randomized Controlled Trial | N = 14 | 82/100 | PMID 21063203 ↗ |
Renovascular hypertension Patient Community & “People Like Me” Threads
Filter Renovascular hypertension community threads and patient logs by age, biological sex, dosage, and treatment duration.